Smithkline Beecham Corporation

Drexel University

Philadelphia Health and Education Corporation

Glaxosmithkline LLC

Irwin M Chaiken

Edward Robert Appelbaum

Robert S Ames

Stephen Dudley Holmes

Mitchell Stuart Gross

Richard M Cook

Lynette Jane McMillan

Timothy Wayne Theisen

Karyn McFadden

Adel Ahmed Rashad Ahmed

Umashankara Muddegowda

Gopi Hosahudya

Elisabeth S Papazoglou

Mark R Contarino

Bibek Parajuli

Hosahudya Gopi

Arangassery Rosemary Bastian

Cameron Frank Abrams

Kantharaju

The present invention includes novel cyclic peptides, and methods of using the same. The present invention further includes novel cyclic peptides conjugated with a gold nanoparticle, and methods of using the same.

Cyclic peptide antiviral agents and methods using same

Cyclic peptides and methods using same

The present invention includes compounds that are useful for treating or preventing a HIV-1 infection in a mammal. In certain embodiments, the compounds cause cell-free virolysis of an HIV-1 virus. The presented invention further includes a method of causing virolysis of a virus using the compounds described therein. The presented invention further includes a method of treating or preventing an HIV-1 infection in a mammal in need thereof using the compositions described therein.

Compositions for promoting HIV-1 virolysis and methods using same

The present invention includes a composition comprising a gold nanoparticle complexed with a cysteine-containing compound. The invention also includes the method of preparing a composition comprising a gold nanoparticle complexed with a cysteine-containing compound. The invention further includes a method of causing virolysis of a virus using the compositions described therein. The invention further includes a method of inhibiting virus entry using the compositions described therein.

Compositions for inhibiting virus entry and promoting virolysis, and methods thereof

The invention provides a peptide triazole conjugate and derivatives thereof, and methods of its use. The invention also provides an antibody to the peptide triazole conjugate. The invention further provides a method of identifying an HIV-1 entry inhibitor candidate.

Active cores of peptide triazole HIV-1 entry inhibitors

The invention provides a peptide triazole conjugate and derivatives thereof, and methods of its use. Further provided are an antibody to the peptide triazole conjugate, and a method of identifying an HIV-1 entry inhibitor candidate.

The invention provides a recombinant multi-functional chimera of CVN and 12p1. Chimeras of CVN and 12p1 present a model for targeting gp120 at two discrete sites, by two different modes of inhibition and with increasing potency versus either component alone. A chimera of the invention combines the high affinity suppression of viral activity by CVN with the allosteric suppression of viral envelope binding to both CD4 and co-receptor by 12p1.

CVN-12p1: a recombinant allosteric lectin antagonist of HIV-1 envelope gp120 interactions

Compounds, which inhibit the binding of gp120 to CD4 as well as 17b and methods for their use in inhibiting the HIV fusion process, are provided.

Dual inhibitors of HIV-1 gp-120 interactions

Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.

Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders

Dual inhibitors of HIV-1 GP-120 interactions

Recombinant IL-5 antagonists useful in treatment of IL-5 mediated

Growing community of inventors

Gladwyne, PA, United States of America

Irwin M Chaiken